文献速递药物不良反应与药物警戒

BRAF与MEK抑制剂相关皮肤不良反应:WHO药物警戒数据真实世界分析

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data.
PubMed 文献 · Clin Pharmacol Ther · 2026-05-24

该研究基于WHO VigiAccess数据库截至2025年5月的七种BRAF/MEK抑制剂个案安全报告,采用报告比值比和比例报告比进行不成比例分析,并用Shannon熵评估毒性谱多样性。结果显示皮肤不良反应在维莫非尼报告中占39.78%,司美替尼占40.03%,且各药物间频率与表型差异显著。

要点

  • 维莫非尼皮肤不良反应报告占比最高(39.78%),司美替尼在MEK抑制剂中最高(40.03%)。
  • 司美替尼痤疮样皮炎报告比值比显著升高(ROR=6.46,95%CI[5.10,8.18])。
  • 光敏反应在维莫非尼(11.31%)和考比替尼(12.02%)中最常报告。

核心结论

  • 皮肤不良反应是MAPK通路抑制剂的标志性毒性,且各药物间频率和表型存在显著差异。
  • 真实世界药物警戒数据支持针对不同药物制定特异性皮肤监测策略。

研究设计与样本

  • 回顾性药物警戒分析,基于WHO VigiAccess数据库截至2025年5月的七种BRAF和MEK抑制剂个案安全报告。
  • 共纳入72,720份个案安全报告,采用报告比值比和比例报告比(含95%CI)进行不成比例分析,并用Shannon熵评估毒性谱多样性。

主要发现

  • 皮肤相关不良反应占维莫非尼报告的39.78%、达拉非尼的16.49%、恩考非尼的14.62%。
  • MEK抑制剂中皮肤相关不良反应比例最高为司美替尼(40.03%),其次为考比替尼(34.31%)。
  • 司美替尼对痤疮样皮炎显示显著不成比例(ROR=6.46,95%CI[5.10,8.18])。
  • 光敏反应最常报告于维莫非尼(11.31%)和考比替尼(12.02%)。
  • Shannon熵分析识别出高多样性组(考比替尼H=3.66;达拉非尼H=3.60)和低多样性组(曲美替尼H=3.51;比美替尼H=3.47),组间比较经Holm-Bonferroni校正后均显著(p<0.05)。

关键数值与推荐

  • 卡方检验证实各药物间皮肤不良反应频率差异显著:BRAF抑制剂χ2(2)=1393.21,p<0.001,Cramér's V=0.255;MEK抑制剂χ2(3)=1129.77,p<0.001,Cramér's V=0.175。
  • 效应量提示临床相关性。

临床怎么用

  • 临床药师应针对不同BRAF/MEK抑制剂制定药物特异性皮肤监测策略,关注高频及特征性不良反应。
  • 早期识别和管理皮肤不良反应有助于提高患者依从性和优化治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600-mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real-world data on dermatologic ADRs are limited. We conducted a retrospective pharmacovigilance analysis of the WHO VigiAccess database, examining individual case safety reports (ICSRs) for seven BRAF and MEKi up to May 2025. Disproportionality analyses (reporting odds ratio (ROR), proportional reporting ratio (PRR), with 95% confidence intervals (CIs)) were performed for high-frequency dermatologic ADRs. Shannon entropy was used to assess the diversity of toxicity profiles across agents. Among 72,720 ICSRs, skin-related ADRs accounted for 39.78% of reports with vemurafenib, 16.49% with dabrafenib, and 14.62% with encorafenib. Among MEKi, the proportion of skin-related ADRs was highest for selumetinib (40.03%) and cobimetinib (34.31%). Rash was the predominant ADR across agents, but selumetinib demonstrated a significant disproportionality for dermatitis acneiform (ROR = 6.46, 95% CI [5.10, 8.18]). Photosensitivity reactions were most frequently reported with vemurafenib (11.31%) and cobimetinib (12.02%). Shannon entropy analysis identified two groups with differing ADR profile diversity: a higher-diversity group (cobimetinib, H = 3.66; dabrafenib, H = 3.60) and a lower-diversity group (trametinib, H = 3.51; binimetinib, H = 3.47); all cross-group comparisons were statistically significant after Holm-Bonferroni correction (p < 0.05). Chi-squared tests confirmed significant differences in skin ADR frequencies among agents (BRAF inhibitors: χ2(2) = 1393.21, p < 0.001, Cramér's V = 0.255; MEKi: χ2(3) = 1129.77, p < 0.001, Cramér's V = 0.175), with effect sizes indicating clinical relevance. Cutaneous ADRs are a defining toxicity of MAPK pathway inhibitors, with substantial interagent variability in frequency and phenotype. Real-world pharmacovigilance data underscore the necessity for agent-specific dermatologic monitoring strategies. Clinical pharmacists play a pivotal role in early ADR detection and management, enhancing adherence and optimizing therapeutic outcomes.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sauer N, Giedziun P, Calik J, et al. Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. Clin Pharmacol Ther. 2026. PMID: 42177750. doi:10.1002/cpt.70326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。